BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36522647)

  • 1. Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma.
    Zhang Z; Wu L; Li J; Chen J; Yu Q; Yao H; Xu Y; Liu L
    J Transl Med; 2022 Dec; 20(1):602. PubMed ID: 36522647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
    Zhang C; Peng L; Gu H; Wang J; Wang Y; Xu Z
    Sci Rep; 2023 Jan; 13(1):1583. PubMed ID: 36709331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
    Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
    Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic biomarker:
    Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J
    Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
    Tian F; Cai D
    Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
    Li S; Xue P; Diao X; Fan QY; Ye K; Tang XM; Liu J; Huang ZY; Tang QH; Jia CY; Xin R; Lv ZW; Liu JB; Ma YS; Fu D
    J Adv Res; 2023 Dec; 54():133-146. PubMed ID: 36716957
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tan Z; Chen M; Peng F; Yang P; Peng Z; Zhang Z; Li X; Zhu X; Zhang L; Zhao Y; Liu Y
    Transl Cancer Res; 2022 Aug; 11(8):2713-2732. PubMed ID: 36093522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
    Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
    Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.
    Qin P; Huang H; Wang J; Jiang T; Zeng N; Wang Q; He Y; Zhou Y
    Med Oncol; 2023 Aug; 40(9):276. PubMed ID: 37612479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
    He D; Zhang X; Tu J
    Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fam198b as a novel biomarker for gastric cancer and a potential therapeutic target to prevent tumor cell proliferation dysregulation.
    Chen B; Diallo MT; Ma Y; Yu W; Yao Q; Gao S; Yu Y; Sun Q; Wang Y; Ren J; Wang D
    Transl Oncol; 2024 Jan; 39():101824. PubMed ID: 37939629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
    Huang FD; Zhong YP; Sun GY; Xu QJ; Xing ZY; Chen KH; Liao LS; Dong MY
    Dig Dis Sci; 2024 Mar; 69(3):1035-1054. PubMed ID: 38282187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
    Yang Y; Zhao W; Du J; Wang Y
    Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3-mediated m6A methylation of ASPM drives hepatocellular carcinoma cells growth and metastasis.
    Wang A; Chen X; Li D; Yang L; Jiang J
    J Clin Lab Anal; 2021 Sep; 35(9):e23931. PubMed ID: 34398984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
    Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X
    Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
    Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
    Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Significance of
    Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.